Business

According to Hi-Tech Pharmacal, sales of its fluticasone propionate nasal spray dropped from $23 million in the 3rd quarter of the 2013 fiscal year to only $10.9 million for the same period in 2014. The… Read more . . .

Verona Pharma has announced that it is looking to raise up to £14 million through a placing, subscription, and open offer of more than 630 million new ordinary shares, conditioned on approval of shareholders. A… Read more . . .

Teva has announced the US launch of Adasuve loxapine inhalation powder for the treatment of agitation in schizophrenic or bipolar patients. The company licensed Adasuve from its developer, Alexza Pharmaceuticals in May 2013. Alexza’s Staccato… Read more . . .

Invion will work with 3M Drug Delivery Systems to develop inhaled formulations of nadolol and zafirlukast to be delivered using 3M’s MDI technology. If inhaled delivery of INV102 (nadolol) and INV104 (zafirlukast) for the treatment… Read more . . .

Sad Diego-based CURx Pharmaceuticals has announced a global license agreement with Gilead Sciences for development of Fosfomycin/Tobramycin for Inhalation (FTI) to treat Pseudomonas aeruginosa lung infection in cystic fibrosis (CF) patients. Gilead initiated a Phase… Read more . . .

Actavis will acquire Forest Laboratories in a deal worth approximately $25 billion, the companies have announced. Both boards of directors have approved the agreement. Forest’s products include the Tudorza Pressair aclidinium bromide DPI, which launched… Read more . . .

Mast Therapeutics has announced that it will acquire Aires Pharmaceuticals, which is developing a sodium nitrite inhalation solution for the treatment of pulmonary arterial hypertension. The inhalation solution, known as AIR001 or “Aironite,” has received… Read more . . .